BeOne Medicines Ltd.
BeOne Medicines (NasdaqGS: ONC) said it entered a multi-part collaboration with Revolution Medicines to access four advanced-stage RAS(ON) inhibitors for oncology. The deal includes joint clinical studies on combination therapies and gives BeOne exclusive development and commercialization rights for these assets in select Asian markets.
BeOne Medicines AG (ONC) and Revolution Medicines, Inc. (RVMD) announced a multi-part clinical collaboration and licensing deal. BeOne will combine select BeOne assets with Revolution’s four RAS(ON) inhibitors and gain exclusive development and commercialization rights in parts of Asia (ex-Japan and South Korea), while Revolution keeps ex-Asia rights and may receive milestones and royalties. BeOne reported Q2 2026 revenue of $1.7B and $6.6–$6.8B full-year guidance; RVMD reported a Q2 2026 net lo
Lee Chan Henry (SVP, General Counsel) sold 2,666 shares of BeOne Medicines Ltd. (ONC) at $360.00 ($0.96M total) on 2026-08-11 under a Rule 10b5-1 trading plan.
Over the past 7 days, alphai's AI scored 4 news stories mentioning BEIGF (BeOne Medicines Ltd.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 0 bearish.
Recent BEIGF coverage spans financial news, insider activity and earnings.
In the last 30 days, BEIGF insiders filed 42 SEC Form 4 transactions — no purchases and 42 sales ($123.3M). The most active reporter was OYLER JOHN, Chief Executive Officer, with 38 filings. 95% of those filings were made under pre-arranged Rule 10b5-1 plans.
BeOne Medicines (NasdaqGS: ONC) said it entered a multi-part collaboration with Revolution Medicines to access four advanced-stage RAS(ON) inhibitors for oncology. The deal includes joint clinical studies on combination therapies and gives BeOne exclusive development and commercialization rights for these assets in select Asian markets.
BeOne Medicines AG (ONC) and Revolution Medicines, Inc. (RVMD) announced a multi-part clinical collaboration and licensing deal. BeOne will combine select BeOne assets with Revolution’s four RAS(ON) inhibitors and gain exclusive development and commercialization rights in parts of Asia (ex-Japan and South Korea), while Revolution keeps ex-Asia rights and may receive milestones and royalties. BeOne reported Q2 2026 revenue of $1.7B and $6.6–$6.8B full-year guidance; RVMD reported a Q2 2026 net lo
Lee Chan Henry (SVP, General Counsel) sold 2,666 shares of BeOne Medicines Ltd. (ONC) at $360.00 ($0.96M total) on 2026-08-11 under a Rule 10b5-1 trading plan.
OYLER JOHN (Chief Executive Officer) sold 240,810 shares of BeOne Medicines Ltd. (ONC) at an average of $359.12 ($350.00–$367.00, $86.48M total) across 24 trades over 2026-08-10 to 2026-08-12 under a Rule 10b5-1 trading plan.
BeOne Medicines (ONC) reported Q2 2026 revenue of $1.7B, up 30%, and GAAP diluted EPS of $2.05, up 144%. BRUKINSA revenue was $1.2B. Full-year 2026 guidance was raised to $6.6B-$6.8B revenue and $1.0B-$1.1B GAAP operating income. Management cited Phase III MANGROVE and real-world Medicare data.
alphai scores every news story that mentions BEIGF with an AI model for sentiment and relevance, and aggregates insider trades from BeOne Medicines Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BeOne Medicines (NasdaqGS: ONC) said it entered a multi-part collaboration with Revolution Medicines to access four advanced-stage RAS(ON) inhibitors for oncology. The deal includes joint clinical studies on combination therapies and gives BeOne exclusive development and commercialization rights for these assets in select Asian markets.
4 min readBeOne Medicines AG (ONC) and Revolution Medicines, Inc. (RVMD) announced a multi-part clinical collaboration and licensing deal. BeOne will combine select BeOne assets with Revolution’s four RAS(ON) inhibitors and gain exclusive development and commercialization rights in parts of Asia (ex-Japan and South Korea), while Revolution keeps ex-Asia rights and may receive milestones and royalties. BeOne reported Q2 2026 revenue of $1.7B and $6.6–$6.8B full-year guidance; RVMD reported a Q2 2026 net lo
6 min readLee Chan Henry (SVP, General Counsel) sold 2,666 shares of BeOne Medicines Ltd. (ONC) at $360.00 ($0.96M total) on 2026-08-11 under a Rule 10b5-1 trading plan.
2 min readOYLER JOHN (Chief Executive Officer) sold 240,810 shares of BeOne Medicines Ltd. (ONC) at an average of $359.12 ($350.00–$367.00, $86.48M total) across 24 trades over 2026-08-10 to 2026-08-12 under a Rule 10b5-1 trading plan.
2 min readBeOne Medicines (ONC) reported Q2 2026 revenue of $1.7B, up 30%, and GAAP diluted EPS of $2.05, up 144%. BRUKINSA revenue was $1.2B. Full-year 2026 guidance was raised to $6.6B-$6.8B revenue and $1.0B-$1.1B GAAP operating income. Management cited Phase III MANGROVE and real-world Medicare data.
7 min readChan Lee, an Oncosec Medical Incorporated (ONC) filer, submitted a Rule 144 notice to sell 718,718 American Depositary Shares (ADS) on NASDAQ. The ADS were acquired in 2002 and are linked to stock option exercises for cash. The sale is set to occur via Morgan Stanley Smith Barney LLC, with an event date of 08/11/2026.
2 min readBeOne Medicines (Nasdaq: ONC) and Revolution Medicines (Nasdaq: RVMD) announced a clinical collaboration to test combinations of BeOne oncology assets with Revolution’s four RAS(ON) inhibitors (daraxonrasib, zoldonrasib, elironrasib, RMC-5127). BeOne also received exclusive development and commercialization rights for these assets in select Asian markets, with milestones and tiered royalties. BeOne will fund a global Phase 3 registrational study for one inhibitor.
4 min readRosenberg Aaron (Chief Financial Officer) sold 1,157 shares of BeOne Medicines Ltd. (ONC) at $312.72 ($0.36M total) on 2026-08-03.
2 min readBeOne Medicines (NASDAQ: ONC) reported Q2 2026 revenue of $1.7B, up 30% y/y, led by BRUKINSA sales of $1.2B (+31%). GAAP diluted EPS was $2.05 per ADS and non-GAAP diluted EPS $3.84. The company raised 2026 revenue guidance to $6.6B-$6.8B and forecast high-80% gross margin, plus updated operating income ranges.
6 min readBeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q22026earningsr.htm EX-99.1 Document Exhibit 99.1 BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates • Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year • BRUKINSA (zanubruti
6 min read
